Jia et al. reported that hepatocyte-specific, but not myeloid cell-specific, TLR4-deficient mice were protected from HFD-induced white adipose tissue inflammation and insulin resistance in spite of obesity and suggested a hepatocyte TLR4-targeted approach as a useful therapeutic strategy of type 2 diabetes [33]. This evidence concerns the gene TLR4 and obesity disorder.